Tandem-multimeric F3-gelonin fusion toxins for enhanced anti-cancer activity for prostate cancer treatment
文献类型：期刊论文
| 作者 | Shin, Meong Cheol2,7,8,9; Min, Kyoung Ah2,3,4,9; Cheong, Heesun5; Moon, Cheol6; Huang, Yongzhuo1 ; He, Huining9; Yang, Victor C.2,9
|
| 刊名 | INTERNATIONAL JOURNAL OF PHARMACEUTICS
 |
| 出版日期 | 2017-05-30 |
| 卷号 | 524期号:1-2页码:101-110 |
| 关键词 | Gelonin Ribosome inactivating protein F3 peptide Prostate cancer Multimeric |
| ISSN号 | 0378-5173 |
| DOI | 10.1016/j.ijpharm.2017.03.072 |
| 文献子类 | Article |
| 英文摘要 | Despite significant progress in prostate cancer treatment, yet, it remains the leading diagnosed cancer and is responsible for high incidence of cancer related deaths in the U.S. Because of the insufficient efficacy of small molecule anti-cancer drugs, significant interest has been drawn to more potent macromolecular agents such as gelonin, a plant-derived ribosome inactivating protein (RIP) that efficiently inhibits protein translation. However, in spite of the great potency to kill tumor cells, gelonin lacks ability to internalize tumor cells and furthermore, cannot distinguish between tumor and normal cells. To address this challenge, we genetically engineered gelonin fusion proteins with varied numbers of F3 peptide possessing homing ability to various cancer cells and angiogenic blood vessels. The E. coli produced F3-gelonin fusion proteins possessed equipotent activity to inhibit protein translation in cell-free protein translation systems to unmodified gelonin; however, they displayed higher cell uptake that led to significantly augmented cytotoxicity. Compared with gelonin fusion with one F3 peptide (F3-Gel), tandem-multimeric F3-gelonins showed even greater cell internalization and tumor cell killing ability. Moreover, when tested against LNCaP s.c. xenograft tumor bearing mice, more significant tumor growth inhibition was observed from the mice treated with tandem-multimeric F3-gelonins. Overall, this research demonstrated the potential of utilizing tandem multimeric F3-modified gelonin as highly effective anticancer agents to overcome the limitations of current chemotherapeutic drugs. (C) 2017 Published by Elsevier B.V. |
| WOS关键词 | RIBOSOME-INACTIVATING PROTEINS ; IRON-OXIDE NANOPARTICLES ; IN-VIVO ; TARGETING PEPTIDES ; ANTITUMOR-ACTIVITY ; ENDOTHELIAL-CELLS ; DRUG-DELIVERY ; BRAIN-TUMORS ; GELONIN ; THERAPY |
| 资助项目 | Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology[NRF-2015R1C1A1A02036781] ; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology[NRF-2015R1A6A3A01020598] ; NSFC A3 Foresight Program[81361140344] ; National Key Basic Research Program of China[2013CB932502] ; National Key Research and Development Plan of China[2016YFE0119200] ; National Institutes of Health[CA114612] |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000401108500010 |
| 出版者 | ELSEVIER SCIENCE BV |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/272653]  |
| 专题 | 药物制剂研究中心 |
| 通讯作者 | Yang, Victor C. |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, 501 Hai Ke Rd, Shanghai 201203, Peoples R China 2.Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, 428 Church St, Ann Arbor, MI 48109 USA; 3.Inje Univ, Coll Pharm, 197 Injero, Gimhae 621749, Gyeongnam, South Korea; 4.Inje Univ, Inje Inst Pharmaceut Sci & Res, 197 Injero, Gimhae 621749, Gyeongnam, South Korea; 5.Natl Canc Ctr, Div Canc Biol, Comparat Biomed Res Branch, 323 Ilsan Ro, Goyang 10408, Gyeonggi Do, South Korea; 6.Sunchon Natl Univ, Coll Pharm, 255 Jungang Ro, Sunchon 57922, Jeonnam, South Korea; 7.Gyeongsang Natl Univ, Coll Pharm, 501 Jinju Daero, Jinju 660751, Gyeongnam, South Korea; 8.Gyeongsang Natl Univ, Res Inst Pharmaceut Sci, 501 Jinju Daero, Jinju 660751, Gyeongnam, South Korea; 9.Tianjin Med Univ, Sch Pharm, Tianjin Key Lab Technol Enabling Dev Clin Therape, Tianjin 300070, Peoples R China; |
| 推荐引用方式 GB/T 7714 | Shin, Meong Cheol,Min, Kyoung Ah,Cheong, Heesun,et al. Tandem-multimeric F3-gelonin fusion toxins for enhanced anti-cancer activity for prostate cancer treatment[J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS,2017,524(1-2):101-110. |
| APA | Shin, Meong Cheol.,Min, Kyoung Ah.,Cheong, Heesun.,Moon, Cheol.,Huang, Yongzhuo.,...&Yang, Victor C..(2017).Tandem-multimeric F3-gelonin fusion toxins for enhanced anti-cancer activity for prostate cancer treatment.INTERNATIONAL JOURNAL OF PHARMACEUTICS,524(1-2),101-110. |
| MLA | Shin, Meong Cheol,et al."Tandem-multimeric F3-gelonin fusion toxins for enhanced anti-cancer activity for prostate cancer treatment".INTERNATIONAL JOURNAL OF PHARMACEUTICS 524.1-2(2017):101-110. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。